The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR antibody that has been approved for use in oncology. Previously we investigated mechanisms of resistance to cetuximab using a model derived from the non-small cell lung cancer line NCI-H226. We demonstrated that cetuximab-resistant clones (Ctx R ) had increased nuclear localization of the EGFR. This process was mediated by Src family kinases (SFKs), and nuclear EGFR had a role in resistance to cetuximab. To better understand SFK-mediated nuclear translocation of EGFR, we investigated which SFK member(s) controlled this process as well as the EGFR tyrosine residues that are involved. Analyses of mRNA and protein expression indicated upregulation of the SFK members Yes (v-Yes-1 yamaguchi sarcoma viral oncogene) and Lyn (v-yes-1 Yamaguchi sarcoma viral-related oncogene homolog) in all Ctx R clones. Further, immunoprecipitation analysis revealed that EGFR interacts with Yes and Lyn in Ctx R clones, but not in cetuximab-sensitive (Ctx S ) parental cells. Using RNAi interference, we found that knockdown of either Yes or Lyn led to loss of EGFR translocation to the nucleus. Conversely, overexpression of Yes or Lyn in low nuclear EGFR-expressing Ctx S parental cells led to increased nuclear EGFR. Chromatin immunoprecipitation (ChIP) assays confirmed nuclear EGFR complexes associated with the promoter of the known EGFR target genes B-Myb and iNOS. Further, all Ctx R clones exhibited upregulation of B-Myb and iNOS at the mRNA and protein levels. siRNAs directed at Yes or Lyn led to decreased binding of EGFR complexes to the B-Myb and iNOS promoters based on ChIP analyses. SFKs have been shown to phosphorylate EGFR on tyrosines 845 and 1101 (Y845 and Y1101), and mutation of Y1101, but not Y845, impaired nuclear entry of the EGFR. Taken together, our findings demonstrate that Yes and Lyn phosphorylate EGFR at Y1101, which influences EGFR nuclear translocation in this model of cetuximab resistance.
INTRODUCTION
Activation of the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK), provides cells with potent growth and survival signals that enable tumors to manifest. 1 --3 Aberrant expression or activity of the EGFR is identified as a major etiological factor in many human epithelial cancers including colorectal cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), breast and brain cancers. 2, 4, 5 In the classical EGFR signaling pathway, ligand binding to the EGFR allows for receptor homo-or heterodimerization at the plasma membrane. This interaction activates each receptor's tyrosine kinase domain and induces autophosphorylation of each dimer's cytoplasmic tail. The phosphorylated cytoplasmic tail of the EGFR serves as docking sites for numerous proteins that initiate key oncogenic pathways including the RAS/ RAF/MEK/ERK and phosphatidylinositol 3-kinase-Akt pathways; however, the activation of src family tyrosine kinases (SFKs), phospholipase C-gamma, protein kinase C and signal transducers and activators of transcription (STAT) proteins have also been documented. 1, 6 In addition to the classical signaling pathways initiated by the EGFR at the cell surface, there is now an emerging novel signaling pathway influenced by EGFR located in the nucleus. The fulllength EGFR can be shuttled from the plasma membrane to the nucleus in a series of well-defined steps. 7 --9 These events include receptor internalization to the early endosome and interaction with importin b1 via its tripartite nuclear localization sequence, followed by COPI-mediated retrograde trafficking to the golgi apparatus and the endoplasmic reticulum. 10, 11 Once in the endoplasmic reticulum the EGFR-importin b1 complex moves to the outer nuclear membrane where importin b1 interacts with nucleoporin 62 lining the nuclear pore channel to shuttle the EGFR-importin b1 complex to the inner nuclear membrane. Here, the complex interacts with the Sec61 b translocon to be released from the membrane into the nucleus. 12, 13 Within the nucleus, EGFR serves as a transcriptional co-activator for a series of tumor-promoting genes including cyclin D1, inducible nitric oxide synthase (iNOS), aurora kinase A, B-Myb, COX2, c-Myc, breast cancer-resistant protein (BCRP) and GRP78.
14 --21 Additionally, nuclear EGFR can phosphorylate and stabilize the proliferating cell nuclear antigen at the replication fork of the dividing cell, 22 and activate DNA-PK to enhance DNA repair. 23 High levels of nuclear EGFR correlate with poor clinical outcome in breast cancer, oropharyngeal squamous cell cancer, ovarian cancer, and gallbladder cancer. 24 --28 Nuclear EGFR also contributes to cancer cells resistance to cetuximab, 29 gefitinib, 20 cisplatin and radiation therapy. 30 --33 Taken together, these pieces of evidence suggest that nuclear EGFR has a role in the promotion of cancer and provides a rationale for studying the mechanisms of EGFR nuclear translocation in order to target the nuclear functions of the EGFR.
It is well established that SFKs are necessary for full activation of the EGFR. 34, 35 Src kinase is the prototypical member of this family of non-RTKs that include Yes (v-Yes-1 yamaguchi sarcoma viral oncogene), Fyn, Lyn (v-yes-1 Yamaguchi sarcoma viral-related oncogene homolog), Lck, Hck Fgr, Blk and Yrk. 36, 37 These SFKs mediate mitogenic signals from a variety of RTKs. 38, 39 It has been observed that SFKs can phosphorylate EGFR at both tyrosine 845 (Y845) and tyrosine 1101 (Y1101). EGFR Y845 is located in the activation loop of the kinase domain that is highly conserved among other RTKs. Phosphorylation of EGFR Y845 appears to be critical for EGFR-mediated mitogenesis, and is critical for the phosphorylation and activation of the STAT5b transcription factor. 34, 40, 41 The second known Src-mediated phosphorylation site is Y1101, which lies within the carboxyl-terminal region of the EGFR; however, the function of Y1101 has not been fully elucidated. 34 Oncogenic cooperation between Src and EGFR has been well established in breast cancer, 34, 42 glioblastoma, 43 HNSCC and NSCLC. 44 --47 We established six clonal Ctx R variants of the NCI-H226 NSCLC line. 29, 48, 49 In previous reports, we found that Ctx R clones had a dramatic increase in nuclear EGFR localization, in addition to having increased SFK activity. 29, 44 Further, we reported that the SFK inhibitor dasatinib (BMS-354825, Sprycel) could (1) block SFK activation, (2) decrease nuclear EGFR translocation, (3) increase plasma membrane levels of the EGFR, and (4) re-sensitize Ctx R cell lines to cetuximab. Collectively, these findings suggest that SFKs have a crucial role in nuclear translocation of the EGFR in this model of cetuximab-resistance. However, the specific SFKs involved in the mediation of EGFR nuclear translocation and how they mediate this process are unknown.
In the current study, we demonstrate that Ctx R clones had increased expression of the SFKs Yes and Lyn. Both Yes and Lyn were strongly associated with EGFR in Ctx R clones as compared to the Ctx S parental cell line. Depletion of either Yes or Lyn kinase decreased EGFR nuclear translocation, and reduced phosphorylation at Y845 and Y1101 of the EGFR. Reciprocally, overexpression of Yes or Lyn increased EGFR nuclear translocation in the Ctx S parental cell line. Furthermore, mutation of Y1101 of the EGFR impaired its nuclear translocation. Collectively, these data suggest that Yes, Lyn and Y1101 of the EGFR are involved in EGFR nuclear translocation in this model of acquired resistance to cetuximab.
RESULTS
The SFK inhibitor Dasatinib blocks nuclear translocation of the EGFR We have previously reported that Ctx R clones have increased nuclear EGFR and activation of SFKs (Figures 1a and b) . 29, 48 Using this model, we determined the effects of the SFK inhibitor dasatinib on the phosphorylation status of the EGFR in three Ctx R clones (HC1, HC4 and HC8) and the Ctx S parental clone (HP) after treatment with 100 nM of dasatinib for 24 h. Dasatinib inhibited the full activation of SFKs as indicated by the loss of phospho-Y419 and decreased the phosphorylation of EGFR at the known SFK phosphorylation sites Y845 and Y1101 (Figure 1b) . Also, treatment with dasatinib led to modest increases in steady-state expression of total SFKs in all Ctx R clones. To determine the effects of dasatinib treatment on nuclear translocation of EGFR, we treated the Ctx R clones and the Ctx S parental clone with 100 nM of dasatinib for 24 h followed by nuclear fractionation. As illustrated in Figure 1c , dasatinib treatment reduced EGFR nuclear translocation in Ctx R clones. The Ctx S parental clone has very low levels of nuclear EGFR and dasatinib treatment had no effect. Thus, the inhibition of SFK activity decreased the phosphorylation of EGFR at Y845 and Y1101 as well as impaired nuclear entry of the EGFR. These results suggested that SFK phosphorylation of EGFR may have a role in inducing its nuclear translocation. (Figure 3a) . Moreover, siYES and siLYN decreased the nuclear localization of EGFR in Ctx R clones (Figure 3b ). Knockdown studies of Yes or Lyn in cells with high nuclear EGFR expression led to decreased nuclear EGFR levels. Therefore, we hypothesized that the overexpression of Yes or Lyn could increase the level of nuclear EGFR in a cell line with low levels of EGFR in the nucleus. To test this hypothesis, we overexpressed Yes or Lyn in Ctx S cells, which express low levels of nuclear EGFR. First, Yes and Lyn were cloned into mammalian expression vectors, expressed in Chinese hamster ovary K1 (CHO-K1) cells and characterized for increased total Yes and Lyn protein expression and activity (Figure 4a ). Comparable increases in Yes and Lyn expression and activation were observed in Ctx S cells after transfection compared with vector only (Figure 4b ). Consistent with siRNA observations, transient transfection of Yes or Lyn into Ctx S cells significantly increased (3 --3.5-fold) nuclear EGFR translocation (Figure 4c ). Interestingly, Yes and Lyn were also detected in nucleus of HP cells after transfection. To determine if Ctx R cells with increased nuclear EGFR also express more Yes and Lyn in the nucleus compared with Ctx S cells, we determined nuclear Yes and Lyn levels in Ctx R clones and Ctx S cells. As seen with EGFR, increased levels of both Yes and Lyn were found in the nucleus of Ctx R clones compared with Ctx S cells (Figure 4d ). These siRNA and overexpression results suggest that Yes and Lyn have a role in EGFR nuclear translocation.
Depletion of Yes or Lyn decreases binding of nuclear EGFR complexes to the B-Myb and iNOS promoter regions Nuclear EGFR and various transcription factor complexes have been shown to bind promoter regions and regulate the transcription of multiple genes including cyclin D1, iNOS, B-Myb, Aurora Kinase A, COX2, c-Myc, BCRP and GRP78. 14 --21 To confirm that nuclear EGFR complexes in Ctx R clones bound to known EGFR target gene promoters, we performed chromatin immunoprecipitation-qPCR (ChIP-qPCR) analysis of the B-Myb and iNOS promoters. We demonstrated that Ctx R clones have increased EGFR association with the B-Myb (3 --9-fold increase in EGFR R HC4 clone we demonstrate that silencing of Yes or Lyn using siRNA reduced nuclear EGFR complex formation with the B-Myb and iNOS promoters as detected by ChIP-qPCR ( Figure 5d ). Additionally, the protein expression of both B-Myb and iNOS were decreased (60 --70%) after siYES or siLYN transfection compared with control NT in HC4 (Figure 5d ).
Collectively, these data demonstrate that Ctx R clones with high levels of nuclear EGFR associate more strongly with known EGFRregulated promoter regions, and that these association (demonstrated with B-Myb and iNOS) can be prevented upon depletion of Yes or Lyn.
EGFR Y1101 is involved in nuclear translocation Analysis of known SFK phosphorylation sites on the EGFR showed increased phosphorylation of Y845 and Y1101 in Ctx R clones ( Figure 1b) . However, the relevance of these two tyrosine sites for EGFR nuclear translocation is unknown. To determine whether phosphorylation of one or both of these tyrosine residues is involved in EGFR nuclear translocation, MCF-7 breast cancer cells (which express very low EGFR levels) were transiently transfected with cDNAs encoding wild-type (WT) EGFR or the following EGFR mutants: EGFR-Y845F or EGFR-Y1101F. Immunoprecipitation of WT and mutant EGFR followed by immunoblotting with antibodies directed against pEGFR Y845 or pEGFR Y1101 showed reduced phosphorylation of Y845 and Y1101. (Figure 6a . Cells were harvested for non-nuclear and nuclear protein, and fractionated on SDS --PAGE followed by immunoblotting for indicated proteins. Histone H3 and a-tubulin were used as loading and purity controls for the nuclear and non-nuclear fractions, respectively. (b) Dasatinib decreased EGFR activity in Ctx R cells. Ctx R clones (HC1, HC4 and HC8) and Ctx S HP cell line were treated with 100 nM dasatinib for 24 h. Cells were harvested and protein lysates were fractionated on SDS --PAGE followed by immunoblotting for the indicated proteins. a-tubulin was used as a loading control. Expression was quantitated using ImageJ software. (c) Dasatinib can inhibit EGFR nuclear translocation in Ctx R clones. Ctx R clones (HC1, HC4, and HC8) and Ctx S cell line (HP) were treated with 100 nM dasatinib for 24 h. Cells were harvested for non-nuclear and nuclear protein, and fractionated on SDS --PAGE followed by immunoblotting for indicated proteins. Histone H3 and a-tubulin were used as loading and purity controls for the nuclear and non-nuclear fractions, respectively. . Cells were harvested and protein lysates were fractionated on SDS --PAGE followed by immunoblotting for the indicated proteins. a-tubulin was used as a loading control. Protein expression was quantitated using ImageJ software. (c) Analysis of EGFR binding partners in Ctx R cells using immunoprecipitation assay indicated that EGFR displayed increased binding with Yes and Lyn as compared with the Ctx S parental cell line. Cells were harvested and EGFR or IgG were immunoprecipitated with anti-mouse EGFR antibody or normal mouse IgG. The immunoprecipitate complexes were fractionated on SDS --PAGE followed by immunoblotting for indicated proteins.
nuclear translocation of the EGFR we treated the transfected cells with epidermal growth factor (EGF) for 45 min before cell lysis and nuclear fractionation. The results of this experiment indicated that EGF was able to induce nuclear translocation of EGFR in both EGFR-WT and EGFR-Y845F mutant cells (Figure 6b ). However, EGFinduced EGFR nuclear translocation was diminished B70% in EGFR-Y1101F mutant cells as compared with EGFR-WT-expressing cells (Figure 6b) . Furthermore, qPCR analysis revealed that B-Myb and iNOS mRNA expression were downregulated in cells transfected with EGFR-Y1101F mutant compared with EGFR-WT-transfected cells (Figure 6c ). Collectively, these data suggest that the phosphorylation of Y1101 is important for the nuclear translocation of EGFR, whereas the phosphorylation of Y845 does not appear to be essential for this process.
DISCUSSION
The nuclear localization of RTKs have been observed for over 20 years; however, only in the past 10 years has research begun to focus on how they translocate from the cell surface to the nucleus and what functions they perform there. All four HER family members have been identified in the nucleus of various types of human cancer cells and tumor specimens.
9,50 --53 Currently, eight target genes of nuclear EGFR have been identified, 14 --21 and nuclear EGFR has been correlated with resistance to cetuximab, radiation, cisplatin and gefitinib therapies. 20,23,29 --33 Collectively, these results suggest an emerging role of the nuclear EGFR signaling network in cancer progression and response to therapeutic modalities.
Several studies have examined how EGFR moves from the plasma membrane to the nucleus of the cell. It has been shown that the full-length EGFR can be shuttled from the plasma membrane to the nucleus through associations with importin b1, the nuclear pore complex, and the Sec61 b translocon. 7, 10, 13 Despite this mechanism of EGFR nuclear translocation, the early events at the plasma membrane that may serve as critical initiating signals for the movement of the EGFR to the nucleus have yet to be defined and form the basis of the current study. Cells were harvested 72 h after treatment with either siYES or siLYN, and protein lysates were fractionated on SDS --PAGE followed by immunoblotting for the indicated proteins. The NT was used as a control. a-tubulin was used as a loading control. Protein expression was quantitated using ImageJ software. (b) siYES and siLYN can reduce the nuclear localization of the EGFR. Cells were harvested for non-nuclear and nuclear protein, and fractionated on SDS --PAGE followed by immunoblotting for indicated proteins after 72 h treatment with either siYES or siLYN. The NT was used as a control. Histone H3 and a-tubulin were used as loading and purity controls for the nuclear and non-nuclear fractions, respectively. Protein expression was quantitated using ImageJ software. . Cells were harvested for non-nuclear and nuclear protein, and fractionated on SDS --PAGE followed by immunoblotting for indicated proteins. Histone H3 and a-tubulin were used as loading and purity controls for the nuclear and non-nuclear fractions, respectively.
To further elucidate the molecular requirements for EGFR nuclear transport we utilized a previously established model of acquired resistance to cetuximab in the NCI-H226 NSCLC cell line. 48 In this model, Ctx R cells were observed to have increased levels of nuclear EGFR as compared with their Ctx S parental cells, making it an ideal model for investigating events involved in nuclear translocation of the EGFR. 29 Additionally, Ctx R cell lines were shown to have increased expression and activity of SFKs. 44 Further investigation using dasatinib, an inhibitor of SFKs, demonstrated that SFK activity was necessary for the nuclear transport of EGFR in this model of cetuximab-resistance. 29 In the current study, we identified Yes and Lyn to have increased expression and association with the EGFR (Figure 2 ). This result is consistent with other reports identifying Yes and Lyn interaction and activation of the EGFR. 54 --57 In addition, loss of Yes and Lyn expression using siRNA technology led to reduced phosphorylation of Y845 and Y1101 of the EGFR and more importantly impaired nuclear EGFR accumulation (Figure 3) . Consistent with this observation, overexpression of Yes and Lyn in Ctx S cells that express low levels of nuclear EGFR significantly increased (3B3.5 fold) nuclear EGFR translocation (Figure 4b ). ChIP assays demonstrated that nuclear EGFR complexes bind to B-Myb and iNOS promoter regions and siYES and siLYN decreased binding to these promoters ( Figure 5 ). Mutagenesis studies of Y845 and Y1101 indicated that Y1101, not Y845, might be necessary for nuclear translocation of the EGFR from the membrane to the nucleus ( Figure 6 ). Recently, Jaganathan et al. 19 reported that Src and EGFR associate in the nucleus with the transcription factor STAT3 to 
m. (n ¼ 3). (c) B-Myb and iNOS protein levels were increased in Ctx
R cells (HC1, HC4, and HC8) as compared with the Ctx S cell line (HP) by immunoblot analysis. Cells were harvested and protein lysates were fractionated on SDS --PAGE followed by immunoblotting for the indicated proteins. a-tubulin was used as a loading control. (d) Loss of Yes or Lyn prevents EGFR association with B-Myb and iNOS promoters, and corresponds with a decrease in protein expression. EGFR-ChIP and subsequent qPCR from the ChIP sample for the presence of B-Myb and iNOS promoter sequences. The NT was used as a control. B-Myb and iNOS protein levels were decreased in HC4 after siYES or siLYN treatment by immunoblot analysis. Cells were harvested after treatment with siLYN or siYES for 72 h and protein lysates were fractionated on SDS --PAGE followed by immunoblotting for the indicated proteins. a-tubulin was used as a loading control.
regulate the expression of the c-Myc gene in pancreatic cancer. Consistent with this report, we found that Yes or Lyn not only increased the levels of nuclear EGFR but also had increased nuclear localization themselves, suggesting that they may have been imported into the nucleus with the EGFR. Collectively, these studies provide evidence for the role of SFKs in mediating nuclear translocation of the EGFR. However, it remains to be investigated whether Yes or Lyn are solely responsible for this nuclear translocation, or if SFKs exhibit a functional redundancy where the overexpression of one or more SFKs may result in the induction of nuclear EGFR in various cancers.
Y845 and Y1101 of the EGFR are phosphorylated by SFKs. 34 Biscardi et al. 34 utilized a GST-bound SH2 domain of the c-Src protein to demonstrate its specific binding to the EGFR via affinity chromatography. Subsequently, these investigators identified and validated that EGFR was indeed phosphorylated by c-Src at Y845 and Y1101. Breast cancer cell lines with high levels of Src activity also had increased levels of phospho Y845 and Y1101 of the EGFR. Researchers further showed that phospho-Y845 was necessary for full EGFR activation and EGF-induced DNA synthesis. 34 This study represented a landmark finding by identifying novel Src phosphorylation sites on the EGFR and the role of tyrosine 845 in the complete activation of the EGFR. Further studies looking at the function of EGFR Y845 demonstrated that Y845 mediated EGFR binding to the mitochondrial protein cytochrome c oxidase subunit II at the mitochondria; however, EGFR Y845 was not necessary for its movement to the mitochondria. 58 These findings support our data that EGFR Y845 may not be required for the intracellular trafficking of the EGFR.
In the current study, we corroborate findings of Biscardi et al. by showing that Y845 and Y1101 are Src-specific phosphorylation sites through the use of the SFK inhibitor dasatinib (Figure 1b) . In addition, siRNA directed towards Yes and Lyn decreased the phosphorylation of EGFR Y845 and Y1101 (Figure 3a) . Our data further suggests that Y1101, not Y845, may be a critical molecular determinant in the localization of nuclear EGFR as indicated by site-directed mutagenesis (Figure 6b ). It should be noted, however, that mutation of Y1101 did not completely block translocation of the EGFR to the nucleus, suggesting that other post-translational modifications of the EGFR may be necessary. Recent evidence has identified another key phosphorylation site on the EGFR, serine 229 (S229), as being necessary for EGFR translocation to the nucleus. 20 It was reported that the serine/ threonine kinase AKT can influence the nuclear translocation of the EGFR by phosphorylating S229 on the EGFR in a model of gefitinib resistance. In this model, gefitinib-resistant A431 cells have both increased AKT activity and increased nuclear EGFR as compared with gefitinib-sensitive A431 cells. Using an antibody that recognizes the phosphorylated consensus motif of AKT substrates and subsequent mass spectrometry, Huang et al. revealed that EGFR was phosphorylated by AKT at S229. 20 Inhibition of AKT kinase activity prevented this phosphorylation event, and decreased the nuclear transport of EGFR, providing evidence for the role of alternative kinases and posttranslational modifications of the EGFR that indeed affect its nuclear translocation. Collectively, these findings suggest that the phosphorylation of the EGFR on Y1101 by Yes and Lyn together with AKT phosphorylation of S229 may be critical molecular determinants that influence the nuclear localization of the EGFR.
EGFR is tightly linked to the etiology of HNSCC, NSCLC, colorectal cancer, breast and brain cancers. Accordingly, five EGFR inhibitors, three tyrosine kinase inhibitors and two monoclonal antibodies, have been developed for clinical use to inhibit EGFR activation and downstream signaling. Despite the successes of these agents, many tumors do not respond to EGFR inhibition, or eventually become resistant to this therapeutic strategy. Accumulating evidence suggests that nuclear EGFR has a role in resistance to radiation, cetuximab, cisplatin and gefitinib therapies. 20,23,29 --33 The mechanisms for how nuclear EGFR leads to this resistance are not clear. However, work from our laboratory suggests that nuclear translocation can protect EGFR from the inhibitory effects of cetuximab causing resistance to this therapy. 29 The results presented in this study provide a potential mechanism for the key molecules involved in nuclear localization of the EGFR providing rational targets to prevent nuclear translocation and thus nuclear function of the EGFR.
In summary, the data presented in the current study has identified the SFKs Yes and Lyn to have a crucial role in nuclear translocation of the EGFR in a model of cetuximab-resistance. In addition, the SFK phosphorylation site Y1101 of the EGFR appears to be involved in translocation of the EGFR from the plasma membrane to the nucleus. These findings are of instrumental value in understanding the molecular requirements for nuclear Figure 6 . Phosphorylation of EGFR at Y1101 is involved in the nuclear localization of EGFR. (a) Immunoprecipitation of total EGFR followed by immunoblotting with anti-pEGFR Y845, anti-pEGFR Y1101 or pan-EGFR antibodies. MCF7 Cells overexpressing EGFR-WT, EGFR-Y845F or EGFR-Y1101F were harvested after stimulation with 100 ng/ml of EGF for 45 min. A total of 500 ug of cell lysate was immunoprecipitated with pan-EGFR antibody. The immunoprecipitates were fractionated on SDS --PAGE followed by immunoblotting for the indicated proteins. (b) Mutation of Y1101, but not Y845, reduces the nuclear localization of EGFR in MCF-7 breast cancer cells. Cells were transiently transfected with plasmids encoding the EGFR WT, EGFR-Y845F, EGFR-Y1101F or vector only. Forty-eight h after transfection the cells were incubated with EGF (100 ng/ml) for 45 min, harvested for whole-cell lysate, non-nuclear, and nuclear protein, and fractionated on SDS --PAGE followed by immunoblotting for indicated proteins. Histone H3 and a-tubulin were used as loading and purity controls for the nuclear and non-nuclear fractions, respectively. (c) B-Myb and iNOS mRNA levels were downregulated in HC4 cells transfected with EGFR-Y1101F mutant compared with EGFR-WT-transfected cells by qPCR. Cells were transiently transfected with plasmids encoding the EGFR-WT or EGFR-Y1101F. Twentyfourth post transfection the cells were treated with EGF (100 ng/ml) for 45 min, and harvested for RNA. The mRNA expression of B-Myb and iNOS was determined by qPCR.
EGFR transport, and for potentially targeting nuclear EGFR in the future.
MATERIALS AND METHODS

Cell lines
The human NSCLC line NCI-H226, the human breast cancer line MCF-7 and CHO-K1 cells were purchased from ATCC (Manassas, VA, USA). The cells were maintained in 10% fetal bovine serum in RPMI-1640 for H226, DMEM/ F12K for MCF-7 and F12K for CHO-K1 (Mediatech Inc., Manassas, VA, USA) with 1% penicillin and streptomycin. The development of cells with acquired resistance to cetuximab has been previously described. 
Cellular fractionation and immunoblotting analysis
Cells were swelled in cytoplasmic lysis buffer (20 mM hydroxyethyl piperazineethanesulfonic acid (HEPES), pH 7.0, 10 mM KCl, 2 mM MgCl 2 , 0.5% NP40, 1 mM Na 3 VO 4 , 1mM phenylmethanesulfonylfluoride (PMSF), 1 mM beta-glycerophosphate (BGP), 10 mg/ml of leupeptin and aprotinin) for 10 min on ice and homogenized by 20 --30 strokes in a tightly fitting Dounce homogenizer. The homogenate was centrifuged at 1500 g for 5 min at 4 1C to sediment the nuclei. The supernatant was then centrifuged at 15 000 g for 10 min at 4 1C, and the resulting supernatant formed the non-nuclear fraction. The nuclear pellet was washed three times in cytoplasmic lysis buffer and re-suspended in the same buffer containing 0.5 M NaCl to extract nuclear proteins. After sonication and vortex, the extracted sample was centrifuged at 15 000 g for 10 min at 4 1C. Whole cell protein lysate was obtained by tween-20 lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 0.1% Tween-20, 10% glycerol, 2.5 mM ethylene glycol tetraacetic acid, 1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM Na 3 VO 4 , 1 mM PMSF, 1 mM BGP and 10 mg/ml of leupeptin and aprotinin). Samples were sonicated and then centrifuged at 15 000 g for 10 min at 4 1C. Protein concentrations were determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts of protein were fractionated by SDS --PAGE, transferred to a polyvinylidene fluoride membrane (Millipore), and analyzed by incubation with the appropriate primary antibody. 
Immunoprecipitation
Cells were lysed with NP-40 lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Deoxycholic acid, 10% glycerol, 2.5 mM ethylene glycol tetraacetic acid, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 1 mM BGP and 10 mg/ml of leupeptin and aprotinin). Cell lysates containing 0.5 mg of protein were incubated overnight at 4 1C with 1 mg of anti-mouse EGFR antibody (Invitrogen) or normal mouse IgG (Cell Signaling Technology). After adding 25 ml of protein A/G agarose beads (Santa Cruz), cell lysates were incubated for another 2 h at 4 1C. The immunoprecipitates were pelleted by centrifugation and washed several times with NP-40 lysis buffer. The captured immunocomplexes were then eluted by boiling the beads in 2 Â SDS sample buffer for 5 min and subjected to immunoblot analysis as described above.
Microarray analysis
Total RNAs extracted from HP, HC1, HC4 and HC8 using an RNeasy kit (Qiagen Inc., Valencia, CA, USA). Gene expression profiling using the HT-HG-U133 Human Genome Array (Affymetrix, Santa Clara, CA, USA) containing over 22 000 well-characterized genes. After Robust Multichip Average (RMA) normalization, data were analyzed using Partek Discovery Suite (St Louis, MO, USA) and signature genes were the genes that increased or decreased 42-fold expression levels in three Ctx R clones (HC1, HC4 and HC8) compared with sensitive parental line (HP) with P-value o0.05.
cDNA synthesis and qPCR cDNA from total RNA of HP, HC1, HC4 and HC8 were synthesized using SuperScript III First-Strand Synthesis System (Invitrogen). qPCR analysis was performed using a Bio-Rad iQ5 Real-Time PCR Detection System (Bio-Rad Laboratories) using the iQ Supermix as recommended by manufacturer. All reactions were performed in triplicate. The sequences of primer sets used for this analysis are as follows: Lyn-F: 5 0 -GGCTCCAGA AGCAATCAACT-3 0 , Lyn-R: ChIP assay Cells were fixed with formaldehyde at a final concentration of 1% for 15 min at room temperature, stopped fixation by 1.25 M glycine for 5 min. Subsequently, cells were washed with ice-cold PBS and collected in the tube and centrifuge at 4 1C for 5 min. The cell pellets were lysed in cell lysis buffer (5 mM HEPES, pH 8.0, 85 mM KCl, 0.5% NP-40 and 10 mM sodium pyrophosphate) by a Dounce homogenizer. After centrifuge, supernatant was removed, and the nuclei pellets were lysed in nuclei lysis buffer (TrisHCl 50 mM, pH 8.1, 10 mM EDTA, 1% SDS and 10 mM sodium pyrophosphate). The lysate was sonicated on ice to shear DNA, and the supernatant was pre-cleared with protein A/G agarose beads (Santa Cruz) in dilution buffer (16.7 mM Tris-HCl, pH 8.1, 1.2 mM EDTA, 167 mM NaCl, 1.1% Triton X-100, 0.01% SDS and 10 mM sodium pyrophosphate) for 1 h at 4 1C. The pre-cleared lysates were immunoprecipitated by incubating with protein A/G beads containing 1 ug of anti-EGFR antibody or IgG and rotated at 4 1C for overnight. The beads were washed with wash buffer I (25 mM Tris-HCl, pH 8.0, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS and 10 mM sodium pyrophosphate), wash buffer II (25 mM Tris-HCl, pH 8.0, 2 mM EDTA, 500 mM NaCl, 1% Triton X-100, 0.1% SDS and 10 mM sodium pyrophosphate), wash buffer III (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 250 mM LiCl, 1% NP-40, 1% deoxycholic acid and 10 mM sodium pyrophosphate) and TE buffer (10 mM Tris-HCl, pH8.0, 1 mM EDTA, 10 mM sodium pyrophosphate). The bound protein was eluted twice with elute buffer (100 mM NaHCO 3 and 1% SDS). Then, 5 M NaCl was added to the pooled eluent and incubated at 68 1C overnight. The DNA was recovered and purified using DNA purification kit (Qiagen). The purified chromatin-immunoprecipitated DNA was used as a template for the qPCR of the promoter regions using the following primer pairs: B-Myb-F: 
